AIDS Research and Treatment / 2012 / Article / Tab 1

Research Article

Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders

Table 1

General characteristics of the 363 HIV-positive patients included in the study.

CharacteristicsPatients = 363

Male gender (n, %)281 (77.4%)
Age, median (years)41 (IQR, 36–46)
HIV transmission route (n, %)
 (i) IVDU157 (43.3%)
 (ii) MSM46 (12.7%)
 (iii) Heterosexual111 (30.5%)
 (iv) Other/unknown49 (13.5%)
Previous AIDS defining event (n, %)109 (30.0%)
CD4 cell count, median (cell/mm3)71 (IQR, 22–162)
Plasma HIV-1 RNA, median (log10cp/mL)4.98 (IQR, 3.81–5.44)
CSF HIV-1 RNA, median (log10cp/mL)3.63 (IQR, 2.17–4.83)
Undetectable CSF HIV-RNA (n, %)60 (16.5%)
Experienced to antiretroviral therapy
(n, %)
182 (50.1%)
Experienced on ARV at neurological diagnosis (n, %)120 (33.1%)
Time on HAART, median (months)16 (IQR, 5–41)
>6 months on HAART before diagnosis (n, %)118 (32.5%)
Cognitive symptoms213 (58.7%)
Abnormal mental status90 (24.8%)
Cerebral atrophy137 (37.7%)
Neurological disorders
 (i) HIVE103 (28.4%)
 (ii) PML 56 (15.4%)
 (iii) PCNSL18 (5.0%)
 (iv) TE36 (9.9%)
 (v) EUO37 (10.2%)
 (vi) CM/TB45 (12.4%)
 (vii) Other diseases 68 (18.7%)

IVDU: intravenous drug users, MSM: men who have sex with men, CSF: cerebrospinal fluid; HIVE: HIV encephalopathy; PML: progressive multifocal leucoencephalopathy; PCNSL: primary central nervous system lymphoma; TE: toxoplasmic encephalitis; EUO: encephalopathies of unknown origin; CM: cryptococcosis; TB: CNS tuberculosis/tubercular meningitis.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.